To assess the effects of treatment with either icosabutate or OCA on fibrosis, hepatic concentrations of hydroxyproline (HYP) were measured via a biochemical assay in addition to type 1 collagen α1 (col1A1) protein content measured via quantitative immunohistochemistry. The gene discussed is COL1A1; the disease is fibrosis.